These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35643868)

  • 21. Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy.
    Cortes JE; Kantarjian HM; Mauro MJ; An F; Nick S; Leip E; Gambacorti-Passerini C; Brümmendorf TH
    Eur J Haematol; 2021 Jun; 106(6):808-820. PubMed ID: 33638218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia.
    Muresan B; Mamolo C; Cappelleri JC; Leip E; Viqueira A; Heeg B
    Curr Med Res Opin; 2021 May; 37(5):801-809. PubMed ID: 33733983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis.
    Takahashi N; Cortes JE; Sakaida E; Ishizawa K; Ono T; Doki N; Matsumura I; García-Gutiérrez V; Rosti G; Ono C; Ohkura M; Tanetsugu Y; Viqueira A; Brümmendorf TH
    Int J Hematol; 2022 Jun; 115(6):838-851. PubMed ID: 35235189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study.
    Rosti G; Brümmendorf TH; Gjertsen BT; Giraldo-Castellano P; Castagnetti F; Gambacorti-Passerini C; Ernst T; Zhao H; Kuttschreuter L; Purcell S; Giles FJ; Hochhaus A
    Leukemia; 2024 Jan; 38(1):126-135. PubMed ID: 38007586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias.
    Cortes JE; Gambacorti-Passerini C; Kim DW; Kantarjian HM; Lipton JH; Lahoti A; Talpaz M; Matczak E; Barry E; Leip E; Brümmendorf TH; Khoury HJ
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):684-695.e6. PubMed ID: 28807791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review.
    Cortes JE; Apperley JF; DeAngelo DJ; Deininger MW; Kota VK; Rousselot P; Gambacorti-Passerini C
    J Hematol Oncol; 2018 Dec; 11(1):143. PubMed ID: 30587215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921.
    Brivio E; Pennesi E; Willemse ME; Huitema ADR; Jiang Y; van Tinteren HDR; van der Velden VHJ; Beverloo BH; den Boer ML; Rammeloo LAJ; Hudson C; Heerema N; Kowalski K; Zhao H; Kuttschreuter L; Bautista Sirvent FJ; Bukowinski A; Rizzari C; Pollard J; Murillo-Sanjuán L; Kutny M; Zarnegar-Lumley S; Redell M; Cooper S; Bertrand Y; Petit A; Krystal J; Metzler M; Lancaster D; Bourquin JP; Motwani J; van der Sluis IM; Locatelli F; Roth ME; Hijiya N; Zwaan CM
    J Clin Oncol; 2024 Mar; 42(7):821-831. PubMed ID: 38033284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
    Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
    Gambacorti-Passerini C; Kantarjian HM; Kim DW; Khoury HJ; Turkina AG; Brümmendorf TH; Matczak E; Bardy-Bouxin N; Shapiro M; Turnbull K; Leip E; Cortes JE
    Am J Hematol; 2015 Sep; 90(9):755-68. PubMed ID: 26040495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial.
    Gambacorti-Passerini C; Brümmendorf TH; Abruzzese E; Kelly KR; Oehler VG; García-Gutiérrez V; Hjorth-Hansen H; Ernst T; Leip E; Purcell S; Luscan G; Viqueira A; Giles FJ; Hochhaus A
    Leukemia; 2024 Oct; 38(10):2162-2170. PubMed ID: 39164407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison.
    Levy MY; McGarry LJ; Huang H; Lustgarten S; Chiroli S; Iannazzo S
    Curr Med Res Opin; 2019 Mar; 35(3):479-487. PubMed ID: 30086654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bosutinib for the treatment of chronic myeloid leukemia.
    Doan V; Wang A; Prescott H
    Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.
    Cortes JE; Jean Khoury H; Kantarjian H; Brümmendorf TH; Mauro MJ; Matczak E; Pavlov D; Aguiar JM; Fly KD; Dimitrov S; Leip E; Shapiro M; Lipton JH; Durand JB; Gambacorti-Passerini C
    Am J Hematol; 2016 Jun; 91(6):606-16. PubMed ID: 26971533
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.
    Kwak JY; Kim SH; Oh SJ; Zang DY; Kim H; Kim JA; Do YR; Kim HJ; Park JS; Choi CW; Lee WS; Mun YC; Kong JH; Chung JS; Shin HJ; Kim DY; Park J; Jung CW; Bunworasate U; Comia NS; Jootar S; Reksodiputro AH; Caguioa PB; Lee SE; Kim DW
    Clin Cancer Res; 2017 Dec; 23(23):7180-7188. PubMed ID: 28939746
    [No Abstract]   [Full Text] [Related]  

  • 35. Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
    Caocci G; Mulas O; Abruzzese E; Iurlo A; Annunziata M; Orlandi EM; Galimberti S; Binotto G; Sgherza N; Luciano L; Martino B; Russo Rossi A; Bonifacio M; Fozza C; Trawinska MM; Cattaneo D; Elena C; Baratè C; De Gregorio F; Molica M; La Nasa G; Foà R; Breccia M
    Ann Hematol; 2019 Aug; 98(8):1885-1890. PubMed ID: 31044260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.
    Hsyu PH; Mould DR; Upton RN; Amantea M
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):209-18. PubMed ID: 23070145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
    Whiteley J; Reisman A; Shapiro M; Cortes J; Cella D
    Curr Med Res Opin; 2016 Aug; 32(8):1325-34. PubMed ID: 27045164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
    Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
    JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.
    Gover-Proaktor A; Granot G; Pasmanik-Chor M; Pasvolsky O; Shapira S; Raz O; Raanani P; Leader A
    Leuk Lymphoma; 2019 Jan; 60(1):189-199. PubMed ID: 29741440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.